Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

This study has been completed.
Sponsor:
Information provided by:
International Extranodal Lymphoma Study Group (IELSG)
ClinicalTrials.gov Identifier:
NCT00210314
First received: September 13, 2005
Last updated: July 22, 2009
Last verified: July 2009
  Purpose

Aim of the study is to establish in a prospective, randomized clinical trial the activity of primary chemotherapy containing high dose-methotrexate, alone or combined with high dose cytarabine, in patients with primary central nervous system lymphoma


Condition Intervention Phase
Lymphoma, B Cell
Drug: high dose methotrexate
Drug: high dose cytarabine
Procedure: radiotherapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Resource links provided by NLM:


Further study details as provided by International Extranodal Lymphoma Study Group (IELSG):

Primary Outcome Measures:
  • The main endpoint is the complete remission (CR) rate after chemotherapy

Secondary Outcome Measures:
  • Overall response rate
  • Response duration (time to relapse or progression) for responder patients
  • Overall survival
  • Event-free survival
  • Meningeal relapse rate
  • Early and late neurotoxicity

Enrollment: 79
Study Start Date: July 2003
Study Completion Date: December 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histological or cytological diagnosis of non-Hodgkin's lymphoma.
  2. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
  3. Disease exclusively localized into the central nervous system, cranial nerves or eyes.
  4. Untreated patients (patients treated with steroids alone are eligible).
  5. At least one measurable lesion.
  6. Age 18 - 75 years.
  7. ECOG performance status < 3
  8. HBsAg-negative and Ab anti-HCV-negative serologic status.
  9. No known HIV disease or immunodeficiency.
  10. Adequate bone marrow (PLT > 100000 mm3, Hb ≥ 9 g/dl, ANC ≥ 2.000 mm3), renal (creatinine clearance ≥ 60 mL/min), cardiac (VEF ≥ 50%), and hepatic function (total serum bilirubin < 3 mg/dL, AST/ALT and gGT < 2 per upper normal limit value).
  11. No previous or concurrent malignancies with the exception of surgically cured cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer and of other cancers without evidence of disease since at least 5 years (patients with a previous lymphoma diagnosis will be excluded).
  12. Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
  13. Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential.
  14. No concurrent treatment with other experimental drugs.
  15. Informed consent signed by the patient before registration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00210314

Locations
Switzerland
Oncology Institute of Southern Switzerland (IOSI)
Bellinzona, Switzerland, 6500
Sponsors and Collaborators
International Extranodal Lymphoma Study Group (IELSG)
Investigators
Study Chair: Andres JM Ferreri, MD Radiochemotherapy. San Raffaele Hospital. Milan
Study Chair: Michele Reni, MD Radiochemotherapy. San Raffaele Hospital. Milan
Study Chair: Emanuele Zucca, MD International Extranodal Lymphoma Study Group/Oncology Institute of Southern Switzerland (IOSI)
  More Information

Additional Information:
No publications provided by International Extranodal Lymphoma Study Group (IELSG)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: International Extranodal Lymphoma Study Group (IELSG), IELSG
ClinicalTrials.gov Identifier: NCT00210314     History of Changes
Other Study ID Numbers: IELSG20
Study First Received: September 13, 2005
Last Updated: July 22, 2009
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Lymphoma
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Cytarabine
Methotrexate
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on August 28, 2014